EyePoint Pharmaceuticals, Inc.(EYPT)

$6.09—

Chart

EyePoint Pharmaceuticals, Inc.(EYPT)

NASDAQ

$6.09—

Chart Studio

EYPT(EYPT)

EYPT

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-0.91

Nov 4, 2026 · Reports before open

Revenue Estimate

$232,154

FY2029E EPS$0.50

FY2030E EPS$2.81

Analyst Sentiment

Wall St. Consensus

Buy

18 analysts·Moderate coverage

Score

13 Buy (72%)5 Hold (28%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

1372%

Hold

528%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$5.00

-18.1%

Consensus

$17.50

+186.7%

Bull

$40.00

+555.4%

12-Month Target Range18 analysts

$5.00$17.50$40.00

Current $6.10Consensus

Current Price

$6.10

Upside to Consensus

$11.40

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+1559.27%

EPS—

FY2028

Rev+754.05%

EPS—

FY2029

Rev+128.15%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$2M	$29M	$252M	$574M	$917M
Low	$1M	$487,469	$16M	$37M	$59M
High	$3M	$86M	$711M	$1.62B	$2.59B
EBITDA Avg	$-2M	$-29M	$-252M	$-574M	$-917M
Low	$-3M	$-86M	$-711M	$-1.62B	$-2.59B
High	$-1M	$-487,469	$-16M	$-37M	$-59M
EBIT Avg	$-2M	$-29M	$-252M	$-574M	$-917M
Low	$-3M	$-86M	$-711M	$-1.62B	$-2.59B
High	$-1M	$-487,469	$-16M	$-37M	$-59M
Net Income Avg	$-311M	$-262M	$-190M	$36M	$206M
Low	$-314M	$-290M	$-267M	$-8M	$-45M
High	$-224M	$-135M	$64M	$122M	$694M
EPS Avg	$-3.75	$-3.01	$-1.62	$0.50	$2.81
Low	$-4.28	$-3.96	$-3.65	$-0.11	$-0.61
High	$-3.06	$-1.84	$0.87	$1.67	$9.47
Analysts (Rev / EPS)	10 / 9	9 / 9	9 / 7	4 / 2	4 / 4

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$289,357	$343,786	$128,250	$128,250	$128,250	$10M
Low	$231,485	$275,028	$102,600	$102,600	$102,600	$8M
High	$347,228	$412,543	$153,900	$153,900	$153,900	$12M
EBITDA Avg	$-289,357	$-343,786	$-128,250	$-128,250	$-128,250	$-10M
Low	$-347,228	$-412,543	$-153,900	$-153,900	$-153,900	$-12M
High	$-231,485	$-275,028	$-102,600	$-102,600	$-102,600	$-8M
EBIT Avg	$-289,357	$-343,786	$-128,250	$-128,250	$-128,250	$-10M
Low	$-347,228	$-412,543	$-153,900	$-153,900	$-153,900	$-12M
High	$-231,485	$-275,028	$-102,600	$-102,600	$-102,600	$-8M
Net Income Avg	$-77M	$-73M	$-61M	$-63M	$-59M	$-52M
Low	$-92M	$-96M	$-77M	$-79M	$-74M	$-65M
High	$-49M	$-54M	$-45M	$-46M	$-44M	$-38M
EPS Avg	$-0.89	$-0.85	$-0.70	$-0.72	$-0.68	$-0.60
Low	$-1.07	$-1.11	$-0.89	$-0.91	$-0.86	$-0.75
High	$-0.56	$-0.62	$-0.52	$-0.53	$-0.51	$-0.44
Analysts (Rev / EPS)	8 / 8	8 / 7	4 / 2	5 / 2	4 / 2	5 / 5

Earnings Surprises

Recent Analyst Actions

Aug 18, 2026Chardan Capital

EyePoint downgraded to Neutral from Buy at Chardan

Target:$5.00

-5.8%from $5.31

Aug 18, 2026RBC Capital

EyePoint downgraded to Sector Perform from Outperform at RBC Capital

Target:$5.00

+2.7%from $4.87

Aug 17, 2026Jefferies

EyePoint price target lowered to $8 from $30 at Jefferies

Target:$8.00

+73.7%from $4.61

Aug 6, 2026H.C. Wainwright

EyePoint price target lowered to $27 from $30 at H.C. Wainwright

Target:$27.00

+120.4%from $12.25

Jul 29, 2026Mizuho Securities

EyePoint Inc. (EYPT) PT Raised to $39 at Mizuho, 'Top Pick'

Target:$39.00

+226.1%from $11.96

Jul 15, 2026Stifel Nicolaus

EyePoint initiated with a Buy at Stifel

Target:$40.00

+188.8%from $13.85

Feb 19, 2026Mizuho Securities

EyePoint price target raised to $36 from $33 at Mizuho

Target:$36.00

+150.7%from $14.36

Feb 5, 2026RBC Capital

RBC Capital on EyePoint Inc. (EYPT): 'We See Recent Weakness as Buying Opportunity'

Target:$39.00

+195.0%from $13.22

Oct 29, 2025Mizuho Securities

EyePoint price target raised to $33 from $28 at Mizuho

Target:$33.00

+169.4%from $12.25

Oct 20, 2025Mizuho Securities

Mizuho Reiterates Outperform Rating on EyePoint Pharmaceuticals, Inc. (EYPT)

Target:$28.00

+140.8%from $11.63

Nov 11, 2024H.C. Wainwright

EyePoint Pharmaceuticals, Inc. (EYPT) PT Lowered to $22 at H.C. Wainwright

Target:$22.00

+89.9%from $11.59

May 13, 2024H.C. Wainwright

EyePoint Pharmaceuticals, Inc. (EYPT) PT Lowered to $30 at H.C. Wainwright

Target:$30.00

+146.5%from $12.17

May 7, 2024Mizuho Securities

EyePoint Pharmaceuticals, Inc. (EYPT) PT Lowered to $30 at Mizuho

Target:$30.00

+167.9%from $11.20

Aug 4, 2022H.C. Wainwright

HC Wainwright & Co. Maintains Buy on EyePoint Pharmaceuticals, Raises Price Target to $25

Target:$25.00

+144.6%from $10.22

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance